Гипертрофия левого желудочка и блокаторы рецепторов к ангиотензину II. От исследований к практическим рекомендациям

1. Aabiti-Rosei E, Muiesan ML. Hypertensive left ventricular hypertrophy: pathophysiological and clinical issues. Blood Pressure 2001; 10:288 298.

2.

3. Jennings G, Wong J. Regression of Left ventricular hypertrophy in hypertension: changing patterns with successive meta-analysis. J Hypertens Suppl 1998; 16:S29-S34.

4.

5. Sen S., Tarazi R.C. Reversal of the myocardial hypertrophy and influence of the adrenergic system. Am J Physiol 1983; 244: H97-H101.

6.

7. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients - A metanalysis of 109 treatment studies. Am J Hypertens 1992;5:95-110.

8.

9. Cruickshank JM, Lewes J, Moore EV, Dodd C. Reversibility of left ventricular hypertrophy by different types of antihypertensive therapy. J Hum Hypertens 1992; 17:85-90.

10.

11. Schmeider RE, Martus P, Klingbeil A., Reversal of left ventricular hypertrophy: analysis of 412 published studies. Am J Hypertens 1994;7:25A.

12.

13. Schmeider RE, Schilachi MP, Klingbeil A, Martus P. Update of Reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996) Nephrol Dial Transplant 1998; 13:564-569.

14.

15. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003 Jul;115(1):41-6.

16.

17. Dahlof В., Himmelman A., Svensson A. Losartan potassium versus atenolol. A comparison of efficiacy, tolerability and effect on left ventricular morphology. Ibid 1995; 27:27-28.

18.

19. Malmqvist K., Kahan Т., Edner M. et al. Regression of left ventricular hypertrophy with irbesartan. J Hypertension 2001; 19:1167-1176.

20.

21. Cuspidi C., Muiesan M.L., Valagussa L. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study.J Hypertens 2002;20(11):2293-2300.

22.

23. Thurmann P, Kenedi P, Schimdt et al. Influence of angiotensin II antagonist Valsartan on Left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98:2037-2042.

24.

25. Wachtell K, Okin PM, Olsen MH et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. Circulation 2007 Aug 14;116(7):700-5.

26.

27. Weber KT, Collagen matrix synthesis and degradation in the development and regression of left ventricular hypertrophy. Cardiovasc Rev Rep 1991; 12:61-69.

28.

29. Varo N., Etayo J.C., Zalba G. et al. Losartan inhibits the post-transcriptional synthesis of collagen type 1 and reverses left ventricular fibrosis in spontaneously hypertensive rats. J Hypertension 1999; 17(1):107-114.

30.

31. Brown L., Fenning A., Shek A., Burtow D. Reversal of cardiovascular remodelling with candesartan. JRAAS 2001; 2(1): S141-S147.

32.

33. Dahlof B. Agabiti-Rosei E, Zaliunas R. Et al. Improvement in left ventricular function following treatment of hypertension with omapatrilat vs losartan. Eur H J 2000; Abst Suppl. p 344 (A1847).

34.